A retrospective multicenter study assessing the real-world outcomes of patients treated with standard of care Idecabtagene vicleucel under the commercial FDA label
Latest Information Update: 11 Jul 2022
At a glance
- Drugs Idecabtagene vicleucel (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
Most Recent Events
- 11 Jul 2022 New trial record
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology